Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 20/20 | 0.83 |
| ▸ | FAAH | O00519 | 13/20 | 0.81 |
| ▸ | AADAC | P22760 | 1/20 | 0.81 |
| ▸ | RAF1 | P04049 | 1/20 | 0.77 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20789010 | 0.91 | EPHX2 (1.00) | EPHX2FAAHAADACRAF1EPHX1 | |
| SCHEMBL19381468 | 0.91 | EPHX2 (1.00) | EPHX2FAAHAADACRAF1EPHX1 | |
| SCHEMBL27004171 | 0.91 | EPHX2 (0.67) | EPHX2FAAHAADACEPHX1 | |
| SCHEMBL19358872 | 0.90 | EPHX2 (1.00) | EPHX2FAAHAADACRAF1EPHX1 | |
| SCHEMBL3180031 | 0.90 | EPHX2 (1.00) | EPHX2FAAHAADACRAF1 | |
| SCHEMBL31114553 | 0.90 | EPHX2 (0.83) | EPHX2FAAHAADACRAF1EPHX1 | |
| SCHEMBL19358873 | 0.90 | EPHX2 (1.00) | EPHX2FAAHAADACRAF1EPHX1 | |
| SCHEMBL655232 | 0.90 | EPHX2 (1.00) | EPHX2FAAHAADACRAF1 | |
| SCHEMBL19358914 | 0.89 | EPHX2 (1.00) | EPHX2FAAHAADACRAF1 | |
| SCHEMBL31114447 | 0.89 | EPHX2 (1.00) | EPHX2FAAHAADACRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150132408-A1 | SORAFENIB DERIVATIVES AS P21 INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-05-14 | — | — | US | disclosed |
| US-9029401-B2 | Sorafenib derivatives as sEH inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-05-12 | — | — | US | disclosed |
| US-20140088156-A1 | SORAFENIB DERIVATIVES AS SEH INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088156-A1 | SORAFENIB DERIVATIVES AS SEH INHIBITORS | EPHX1, FAH, EPHX2 | EPHX2 3/4885FAAH 84/4885AADAC 2104/4885 |
| US-20150132408-A1 | SORAFENIB DERIVATIVES AS P21 INHIBITORS | TP53, CDKN1A, HCCS | EPHX2 2775/4885FAAH 4763/4885AADAC 2076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.